Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8mL dose.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

This marks the second BTD for petosemtamab in HNSCCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and ...

CJ Bioscience announced today that it will present preclinical data on its novel drug candidate CJRB-201 at the European ...

US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...